Misonix BoneScalpel™ Highlighted In New Clinical Paper Aimed At Face And Jaw Surgery

 Misonix BoneScalpel™ Highlighted In New Clinical Paper Aimed At Face And Jaw
                                   Surgery

PR Newswire

FARMINGDALE, N.Y., March 5, 2013

FARMINGDALE, N.Y., March 5, 2013 /PRNewswire/ --Misonix, Inc. (NasdaqGM:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, announces a new clinical
paper accepted for publication by "The International Journal of Oral &
Maxillofacial Surgery," a well-respected, peer-reviewed journal. Entitled
"Ultrasonic Orthognathic Surgery; Enhancements to Established Osteotomies,"
authored by Gilles, Couvreur and Dammous, from the Department of Oral and
Maxillofacial Surgery, Clinique de Esperance, Montegnee, Belgium, the clinical
paper is circulated to leading oral, maxillofacial and reconstructive
surgeons. Orthognathic surgery refers to the correction of abnormal conditions
affecting the jaw or face; osteotomies refer to the bone dissection (cutting)
necessary to reposition bone during these surgeries. Given the attributes of
the Misonix BoneScalpel, as described below, the use of traditional power
instruments, such as saws or burrs, was unnecessary for this study.

It was noted that the Misonix® BoneScalpel Ultrasonic Bone Cutter (osteotome)
offers a safe and efficient method to create precise cuts during the
transection of bone during reconstructive surgery of the jaw and face,
generally required as a result of birth defects and other abnormalities.
Primary advantages, as reported, include improved control, a largely bloodless
operative field for improved visualization, precise osteotomies (cuts through
bone), significant reductions in the occurrence of nerve impairment, and
significant reductions in 'bad bone splits' that may require additional
corrective surgery.

In the words of Dr. Roland Gilles, MD, DDS, one of the clinical investigators;
"We adapted the ultrasonic blade of the BoneScalpel to serve as a universal
instrument for orthognathic and maxillofacial surgery. We have since performed
well over 100 procedures including orthognathic, reconstructive and oncologic
surgeries. Using the BoneScalpel, we have much better control over the
osteotomy and have observed significantly fewer bad splits and reductions in
nerve impairment, swelling, hematoma, operative time and hospital stay."

The Misonix® BoneScalpel™, which was used to perform the study, is a novel
ultrasonic osteotome (bone cutting device) used for safe, tissue-selective
bone dissection that encourages en-bloc bone removal and refined osteotomies
while sparing elastic soft tissue structures. Most users report that the
surgical field is relatively bloodless and clean. Loss of viable bone is
minimal and controllable. In addition to maxillofacial and reconstructive
surgery, the BoneScalpel has been used extensively for bone removal in the
cervical, thoracic and lumbar spine, including spinal deformity surgery.

"We are proud to report such an impressive clinical experience with the
Misonix BoneScalpel when used in advanced orthognathic surgery," said Michael
A. McManus, Jr., President and Chief Executive Officer of Misonix. "In many
procedures in spine surgery, as well as maxillofacial surgery, we are now
seeing that surgeons are finding less bleeding, as was observed by Dr. Gilles,
et al, which contributes to faster, safer procedures that require less time in
the hospital. It is our privilege to work with world renowned surgeons and to
provide state of the art ultrasonic surgical technology to prestigious
institutions throughout the world."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

                   Investor Relations Contacts
Misonix Contact:   Lytham Partners, LLC
Richard Zaremba    Robert Blum, Joe Dorame, Joe Diaz
631-694-9555       602-889-9700
invest@misonix.com mson@lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
 
Press spacebar to pause and continue. Press esc to stop.